How inherited cancer risks can be used for effective personalized therapy
Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...
Clinical Trials Arena on MSN5d
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment
Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.
News-Medical.Net on MSN4d
Study uncovers protective mechanism of BRCA2 in cancer treatment
Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...
MedPage Today6d
Survival Benefit in Metastatic CRPC Study Spurs Questions on Patient Selection
In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake ...
Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...
Wedbush Reaffirms “Outperform” Rating for Nuvation Bio (NYSE:NUVB)
Wedbush restated their outperform rating on shares of Nuvation Bio (NYSE:NUVB – Free Report) in a research report report published on Thursday morning,RTT News reports. Wedbush currently has a $5.00 ...
Targeted Oncology5d
Expanding HRD and BRCA1/2 Testing Could Improve Access to Effective Treatments in Ovarian and Breast Cancer
A real-world study reveals the need for increased homologous repair deficiency and BRCA1/2 testing in patients with ovarian ...
Bianca Balti's Unyielding Fight
Two months after the last chemotherapy, Bianca Balti resumes her battle against cancer. Fresh from participating in the Milan ...